

POSTER PRESENTATION

Open Access

# P64. T cell re-direction against Glypican-3 for immunotherapy of hepatocellular carcinoma

C Dargel<sup>1\*</sup>, M Bassani-Sternberg<sup>2</sup>, K Krebs<sup>1</sup>, S Wilde<sup>3</sup>, D Schendel<sup>3</sup>, DH Busch<sup>4</sup>, M Mann<sup>2</sup>, U Protzer<sup>1</sup>

From 1st Immunotherapy of Cancer Conference (ITOC1)  
Munich, Germany. 12-14 March 2014

Hepatocellular carcinoma (HCC) is the third most common cause of cancer related mortality world-wide and therapeutic options are very limited. A new therapeutic approach is the adoptive T cell therapy of HCC. Glypican-3 (GPC3) as a tumour associated antigen is expressed in up to 60% of all HCC but not in healthy human liver tissue. Therefore, our goal is to generate cytotoxic T lymphocytes (CTL), which are capable of recognizing and eliminating GPC3-expressing tumor cells.

Immunodominant epitopes for GPC3 have not been described yet. In this study we used Ultra Nano HPLC coupled on-line to the Q Exactive mass spectrometer to obtain a comprehensive HLA class I peptidome from a GPC3 and HLA-A2 positive hepatoma cell line. The resulting data were analysed using the MaxQuant bioinformatics platform. Two HLA-A2 bound GPC3 peptides could be identified, later on referred to as GPC3-P1 and GPC3-P2. These results enable us to target GPC3 epitopes that are presented on GPC3 positive HCC cells.

To isolate tumour reactive high avidity T cells, an allo-restricted stimulation approach was used. For stimulation of naïve T cells, autologous dendritic cells were co-transfected with GPC3 and HLA-A2 RNA and used as antigen presenting cells. T cells from the naïve T cell repertoire of HLA-A2 negative donors were co-cultured with and expanded on these HLA-A2+ GPC3+ DCs. After two weeks, MHC streptamer-positive CD8<sup>+</sup> T cells specific for both targeted GPC3 epitopes were detected (<1%). We were able to enrich these cell populations further to 35% GPC3-P1- and 57% GPC3-P2-MHC streptamer-positive T cell lines and grew T cell clones from them. In a co-culture with GPC3-P1/ -P2 peptide loaded T2 cells we identified T cell clones displaying specific effector function by IFN $\gamma$  secretion. Functional T cell clones showed strong GPC3 MHC streptamer binding.

We have cloned the first T cell receptors (TCR) to either GPC3 peptide from these T cell clones. T cells engrafted with the GPC3 specific TCRs showed strong GPC3 MHC streptamer binding. When co-cultured with GPC3 peptide loaded target cells or a GPC3 expressing hepatoma cell line (HepG2), GPC3 TCR transduced T cells secreted IFN $\gamma$ . Furthermore cytotoxicity was observed by killing of up to 60% of HepG2 cells. GPC3-directed T cell therapy shows great promise for the treatment of HCC.

#### Authors' details

<sup>1</sup>Institute of Virology, Technische Universität, München, Germany. <sup>2</sup>Institute of Biochemistry, Max-Planck-Institute, München, Germany. <sup>3</sup>Institute of Molecular Immunology, Helmholtz Zentrum, München, Germany. <sup>4</sup>Institute for Medical Microbiology Immunology and Hygiene, Technische Universität, München, Germany.

Published: 12 March 2014

doi:10.1186/2051-1426-2-S2-P38

Cite this article as: Dargel et al.: P64. T cell re-direction against Glypican-3 for immunotherapy of hepatocellular carcinoma. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 2):P38.

#### Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



<sup>1</sup>Institute of Virology, Technische Universität, München, Germany  
Full list of author information is available at the end of the article